OncLive Staff


Tarantino Previews Exciting Research in HER2-Low Breast Cancer

May 26th 2022

Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma

May 19th 2022

Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.

Pal Discusses Eye-Catching ASCO GU Data in RCC

May 16th 2022

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.

Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer

May 12th 2022

Dr Pegram discusses approaches to treatment sequencing in HER2-positive metastatic breast cancer, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.

Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC

May 9th 2022

Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

Borgen Recommends Revamping Peer Review for a Post-COVID-19 World

May 5th 2022

Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendations for fixing peer review, and explaining how this affects cancer research.

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians associated with the doublet, and the potential next steps for this therapy in melanoma.

ODAC Unanimously Votes to Recommend Randomized Data for Approval of PI3K Inhibitors in Hematologic Cancers

April 21st 2022

In a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K inhibitors on randomized data instead of single-arm clinical trials.

Bardia Reflects on Important Data in HER2+ Breast Cancer

April 21st 2022

Dr Bardia discusses data from DESTINY-Breast03, HER2CLIMB, and NALA, important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.

Trimodality Approach to MIBC Paves Path for Bladder Preservation

April 20th 2022

Standard chemoradiation therapy regimens have had marked success for patients with muscle-invasive bladder cancer; however, up to 30% of patients who receive treatment with bladder preserving intent will have recurrence.

D'Abreo Addresses AEs in Metastatic Breast Cancer Care

April 14th 2022

Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.

Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis

April 7th 2022

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

FDA Approval Insights: Pacritinib in Myelofibrosis

March 31st 2022

Dr Mesa discusses the data that led to the FDA approval of pacritinib, toxicities clinicians should be aware of when prescribing the JAK inhibitor, and the next steps for pacritinib in the space.

Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022

March 24th 2022

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.

Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma

March 23rd 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Lyle and Patel Examine Diagnostic and Management Paradigms in MDS

March 17th 2022

Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment landscape, and the role of next-generation sequencing and optimal testing practices in the field.

Top 8 Trials From 2021 in Breast Cancer

March 16th 2022

Leading oncologists in breast cancer share their perspectives on the biggest abstracts that were presented throughout 2021 .

Ross Reflects on Surgical Advances and Changing Trends in CRC

March 10th 2022

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.

Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer

March 3rd 2022

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.